NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors NEO212™ completes initial two cohorts of Phase 1 study under FDA Investigative New Drug (IND).Study tests the safety of NeOnc’s patented novel drug, NEO212™, which is the bioconjugation of its leading...

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status New investment and debt conversion by new and existing investors sets company’s post-money valuation at approximately $220 million, up 214% from previous funding round.Financing supports further...

NeOnc Technologies Appoints Sidra Medicine CEO and Forbes Top 100 Healthcare Leader, Dr. Iyabo Tinubu-Karch, to Scientific Advisory Board LOS ANGELES, April 18, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has appointed Dr. Iyabo Tinubu-Karch to its scientific advisory...

NeOnc Technologies CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’ LOS ANGELES and CHICAGO and LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings Inc., a clinical stage medical biotechnology company, announced that its CEO, Thomas Chen, MD,...

NeOnc Technologies Completes $10.0 Million Equity Funding Round LOS ANGELES, Feb. 08, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has completed a $10.0 million equity funding round at a post-money...